Perceptive Advisors’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Perceptive Advisors’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-329,890	Closed	-$28.8M	–	155
2020 Q3	$28.8M	Hold	329,890	–	–	0.42%	55
2020 Q2	$21.3M	Sell	329,890 -20,000	-6%	-$1.15M	0.35%	59
2020 Q1	$15.4M	Sell	349,890 -87,500	-20%	-$4.65M	0.4%	47
2019 Q4	$27.2M	Sell	437,390 -159,800	-27%	-$7.6M	0.54%	42
2019 Q3	$22.5M	Buy	597,190 +172,222	+41%	+$7.5M	0.6%	40
2019 Q2	$17.3M	Buy	+424,968	New	+$15.2M	0.4%	51

Other funds holding TPTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Perceptive Advisors's TPTX Position: Q4 2020 in Review

Perceptive Advisors sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q4 2020, closing a stake of 329,890 shares — an estimated $28.8M sold.

Perceptive Advisors first reported a position in TPTX in Q2 2019 and held it in 6 quarters. The position peaked at $28.8M in Q3 2020. 193 funds tracked by Wall St. Rank hold TPTX as of Q4 2020.

Perceptive Advisors reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Perceptive Advisors sold 329,890 Turning Point Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $28.8M.
Perceptive Advisors first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 6 quarters.
Perceptive Advisors's Turning Point Therapeutics, Inc. Common Stock position peaked at $28.8M in Q3 2020.
193 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Perceptive Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.